Cargando…
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
Obesity,and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically to increase the risk of adverse clinical outcomes (both hepatic and extrahepatic). Type 2 diabetes mellitus (T2DM) is the...
Autores principales: | Ding, Yuping, Deng, Quanjun, Yang, Mei, Niu, Haiyan, Wang, Zuoyu, Xia, Shihai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613411/ https://www.ncbi.nlm.nih.gov/pubmed/37905232 http://dx.doi.org/10.2147/DMSO.S431251 |
Ejemplares similares
-
FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023) -
Implications of metabolic dysfunction associated fatty liver disease in COVID-19
por: Chakraborty, Raja, et al.
Publicado: (2023) -
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
por: Zhou, Xiao-Dong, et al.
Publicado: (2022) -
Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults
por: Shi, Ameng, et al.
Publicado: (2023) -
Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease
por: Lee, Chi-Ho, et al.
Publicado: (2023)